MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
May 13, 2024 07:30 ET
|
MiNK Therapeutics
Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board...
Enovix Begins Customer Sampling of EX-1M Batteries
May 13, 2024 07:30 ET
|
Enovix Corporation
FREMONT, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced that it has begun customer sampling of its...
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
May 13, 2024 07:30 ET
|
BridgeBio Pharma, Inc.
- In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality...
Akoustis Reports Third Quarter FY24 Results
May 13, 2024 07:30 ET
|
Akoustis, Inc.
Q3 Revenue Up 7% Quarter-Over-Quarter Filter-Related Revenue Up 13% Quarter-Over-Quarter, Third Highest in Company History Growth, Cost Savings Initiatives, CHIPS Act ITC Refund Support...
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
May 13, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – –...
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
May 13, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024 07:30 ET
|
Avalo Therapeutics
Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 ...
Encore Capital Group, Inc. Announces Proposed Senior Secured Notes Offering
May 13, 2024 07:17 ET
|
Encore Capital Group, Inc.
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Encore Capital Group, Inc. (Nasdaq: ECPG) (the “Company”) today announced its intention to offer, subject to market and other conditions, $400.0 million...
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
May 13, 2024 07:15 ET
|
Milestone Pharmaceuticals Inc.
– NDA for etripamil in PSVT resubmitted in 1Q 2024– Cash resources as of March 31, 2024 expected to fund operations into 2026– Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR...
Draganfly to Host Shareholder Update and Q1 Earnings Call
May 13, 2024 07:15 ET
|
Draganfly Inc
Saskatoon, SK., May 13, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems...